Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica C Hassel

Showing results (141-150 of 272) with videos related to

Pageof 28
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 21, 2018
Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancyChristian Menzer, Bernd Beedgen, Joachim Rom, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 8, 2014
Comparison of molecular abnormalities in vulvar and vaginal melanomasSebastian Aulmann, Hans P Sinn, Roland Penzel, et al.
ESMO Open|June 25, 2019
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and managementLucie Heinzerling, Thomas K Eigentler, Michael Fluck, et al.
Cancers|July 14, 2023
Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint InhibitionJessica C Hassel, Lisa Zimmer, Thomas Sickmann, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2022
MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective studyMartin Salzmann, Johannes Pawlowski, Carmen Loquai, et al.
Cancers|June 13, 2025
Interleukin-4 and -13 Gene Expression Profiles in Immune-Related Bullous Pemphigoid Indicate Efficacy of IL-4/IL-13 InhibitorsLisa Arnold, Monika Morak, Nora Kramer, et al.
Cancers|December 11, 2025
Correction: Hassel et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. <i>Cancers</i> 2023, <i>15</i>, 3448Jessica C Hassel, Lisa Zimmer, Thomas Sickmann, et al.
Trials|April 21, 2021
Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trialPia Grabbe, Kathrin M Gschwendtner, Imad Maatouk, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2013
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsSimone M Goldinger, Lisa Zimmer, Carsten Schulz, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 18, 2025
Monitoring soluble cMET and ctDNA in metastatic uveal melanoma patients to track early disease progression on immunotherapiesDevayani Machiraju, Christian H Ziener, Elena Clementi, et al.
Pageof 28

Showing results (141-150 of 272) with videos related to

Sort By:
Pageof 28
European Journal of Cancer (Oxford, England : 1990)|November 21, 2018
Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancyChristian Menzer, Bernd Beedgen, Joachim Rom, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 8, 2014
Comparison of molecular abnormalities in vulvar and vaginal melanomasSebastian Aulmann, Hans P Sinn, Roland Penzel, et al.
ESMO Open|June 25, 2019
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and managementLucie Heinzerling, Thomas K Eigentler, Michael Fluck, et al.
Cancers|July 14, 2023
Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint InhibitionJessica C Hassel, Lisa Zimmer, Thomas Sickmann, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2022
MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective studyMartin Salzmann, Johannes Pawlowski, Carmen Loquai, et al.
Cancers|June 13, 2025
Interleukin-4 and -13 Gene Expression Profiles in Immune-Related Bullous Pemphigoid Indicate Efficacy of IL-4/IL-13 InhibitorsLisa Arnold, Monika Morak, Nora Kramer, et al.
Cancers|December 11, 2025
Correction: Hassel et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. <i>Cancers</i> 2023, <i>15</i>, 3448Jessica C Hassel, Lisa Zimmer, Thomas Sickmann, et al.
Trials|April 21, 2021
Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trialPia Grabbe, Kathrin M Gschwendtner, Imad Maatouk, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2013
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsSimone M Goldinger, Lisa Zimmer, Carsten Schulz, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 18, 2025
Monitoring soluble cMET and ctDNA in metastatic uveal melanoma patients to track early disease progression on immunotherapiesDevayani Machiraju, Christian H Ziener, Elena Clementi, et al.
Pageof 28